Harris S T, Genant H K, Baylink D J, Gallagher J C, Karp S K, McConnell M A, Green E M, Stoll R W
Department of Medicine, University of California, San Francisco 94143.
Arch Intern Med. 1991 Oct;151(10):1980-4.
The effects of cyclical treatment with estrone sulfate (0.3, 0.625, or 1.25 mg), plus calcium carbonate, on spinal trabecular bone density were compared with placebo in 120 postmenopausal women in this 2-year, multicenter, double-blind study. While the placebo and 0.3-mg treatment groups lost bone density (-3.6% and -5.1%), the 0.625- and 1.25-mg treatment groups experienced no significant change from baseline at 24 months (-0.8% and +0.7%). The 1.25-mg treatment group was significantly different from the placebo group at 12, 18, and 24 months. Although the 0.625-mg treatment group was significantly different from the placebo group only at 18 months, the data suggest that 0.625 and 1.25 mg of estrone sulfate had different effects than placebo and 0.3 mg of estrone sulfate and, given with supplemental calcium, are effective doses for the prevention of spinal bone loss.
在这项为期两年的多中心双盲研究中，120名绝经后女性被用于比较硫酸雌酮（0.3、0.625或1.25毫克）联合碳酸钙的周期性治疗对脊柱小梁骨密度的影响与安慰剂的效果。安慰剂组和0.3毫克治疗组骨密度下降（分别为-3.6%和-5.1%），而0.625毫克和1.25毫克治疗组在24个月时与基线相比无显著变化（分别为-0.8%和+0.7%）。1.25毫克治疗组在12、18和24个月时与安慰剂组有显著差异。虽然0.625毫克治疗组仅在18个月时与安慰剂组有显著差异，但数据表明，0.625毫克和1.25毫克硫酸雌酮与安慰剂及0.3毫克硫酸雌酮的作用不同，且补充钙后，它们是预防脊柱骨质流失的有效剂量。
